NDATOPICALSHAMPOO
Approved
Feb 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
19
Data completeness
6/8 — Strong
CLOBEX (clobetasol propionate) by Galderma is corticosteroids, clobetasol propionate shampoo, 0. Approved for psoriasis, atopic dermatitis. First approved in 2004.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLOBEX is a topical corticosteroid shampoo (clobetasol propionate 0.05%) approved in 2004 for inflammatory scalp and skin conditions including psoriasis, atopic dermatitis, and seborrheic dermatitis. It works by inducing lipocortin proteins that inhibit phospholipase A2, thereby reducing the biosynthesis of inflammatory mediators like prostaglandins and leukotrienes. The drug is administered topically as a shampoo formulation.
$0.135MPart D
LOE ApproachingProduct is in late lifecycle stage with minimal Part D volume and low commercial priority relative to high-spending dermatology competitors.
Mechanism of Action
corticosteroids, Clobetasol Propionate Shampoo, 0.05%, has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase…
Indications (2)
Worked on CLOBEX at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.